Search the Newsreel

Nantahala Capital (QNCX) reports 0% stake in Quince Therapeutics in latest 13G/A

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 0% beneficial ownership in Quince Therapeutics, Inc. as of June 30, 2026. This Schedule 13G/A filing indicates that they hold no shares and possess no voting or dispositive power over …

Quince Therapeutics (QNCX) books $39.6M loss but lifts cash to $116M

Quince Therapeutics Q2 EPS of $(12.31) beats $(26.32) estimate

Quince Therapeutics (NASDAQ: QNCX) significantly beat Q2 2026 EPS estimates with a loss of $(12.31) against a consensus of $(26.32), marking an 81.9% improvement year-over-year. The company completed its acquisition of Orphai Therapeutics and raised $115 million in a private placement, strengthening its cash …

Form 8K Quince Therapeutics Inc For: 14 August By Investing.com

This article reports on the filing of a Form 8K by Quince Therapeutics Inc. on August 14. The financial document is brief and focuses solely on this specific filing for the mentioned date. It appears to be a standard notification without extensive details provided …

Quince Therapeutics reports $75.5M Q2 net loss, $116M cash as of June 30, 2026

Quince Therapeutics announced a net loss of $75.5 million for Q2 2026, with $116 million in cash, cash equivalents, and investments as of June 30, 2026. The company completed a $115 million private placement concurrent with its acquisition of Orphai and initiated a Phase …

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Quince Therapeutics announced its second-quarter 2026 financial results, highlighting the acquisition of Orphai Therapeutics and its lead program, LAM-001, which targets serious pulmonary diseases. The company also completed a $115 million private placement financing, bolstering its cash reserves to fund operations through 2028. Clinical …

Quince Therapeutics (QNCX) updates S-3 shelf with legal opinion and $498K in costs

Quince Therapeutics (QNCX) has filed an S-3 amendment to add a legal opinion as Exhibit 5.1 to its shelf registration statement, with no changes to the substantive terms. The amendment details estimated offering-related expenses of $498,600, including legal and SEC fees, which the company …

Quince Therapeutics (QNCX) sees Squadron group report 5.6% ownership stake

A Schedule 13G filing reveals that Squadron Master Fund LP and related entities, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, collectively reported a beneficial ownership of 5.6% in Quince Therapeutics (QNCX). This ownership amounts to 55,173 shares of common stock, based …

Quince Therapeutics Announces Leadership Transition to Orphai Team

Quince Therapeutics announced a leadership transition following conditional resignations from its CEO and COO, effective after a special shareholder meeting on September 25, 2026, pending shareholder approval of proposals related to the Orphai acquisition. The company's board has approved conditional appointments of Orphai veterans …

Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

Form PRE 14A Quince Therapeutics Inc For: 1 August By Investing.com

This article reports on the filing of Form PRE 14A by Quince Therapeutics Inc. on August 1st. The brief note also includes the company's stock symbol QNCX and its current performance of +1.56%.

QNCX Stockholders Plan to Sell 15.47M Shares Amid Unprofitable Biotech Landscape

Quince Therapeutics Inc (NASDAQ: QNCX) stockholders plan to sell 15.47 million shares, a move that the company itself will not participate in. Despite a high Price-to-Sales ratio of 22.87, the pre-revenue biotech firm has a low GF Score™ of 25 out of 100, indicating …

Quince Therapeutics (QNCX) files resale for 15.5M shares tied to Orphai deal

Quince Therapeutics (QNCX) has filed to register 15.5 million shares of Common Stock for resale by existing selling stockholders. These shares are linked to the company's acquisition of Orphai Therapeutics and a 2026 private placement. Quince will not receive direct proceeds from the resale …

Quince Therapeutics announces special shareholder meeting

Quince Therapeutics will hold a virtual special shareholder meeting in September 2026 to vote on several key proposals. These include converting Series C Preferred Stock to common stock, issuing common stock for warrant exercises and Orphai options, and increasing authorized common shares from 250,000,000 …

Quince Therapeutics (QNCX) seeks approval for Orphai merger dilution and $115M PIPE

Oppenheimer Initiates Quince Therapeutics at Outperform With $82 Price Target

Oppenheimer has initiated coverage of Quince Therapeutics (QNCX) with an "Outperform" rating and set a price target of $82. This positive analyst recommendation suggests that Oppenheimer believes the stock will perform better than the broader market and has significant upside potential. The latest news …

Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Quince Therapeutics Inc (QNCX), listing major individual and institutional holders, their proportional ownership, and recent changes in their holdings. It also categorizes shareholders by type, such as hedge funds and individual investors, and provides institutional shareholding trends …

Quince Therapeutics Inc (QNCX) Cash Flow

This article provides a detailed cash flow statement for Quince Therapeutics Inc (QNCX), including quarterly and annual data for operating, investing, and financing cash flows. It also defines these cash flow types and presents key figures and year-over-year changes for the company, such as …

QNCX|Quince Therapeutics Inc|Price:17.740|Chg%:-0.540

Quince Therapeutics Inc. (QNCX) is a late-stage biotechnology company focused on developing life-changing therapeutics for rare diseases using its proprietary autologous intracellular drug encapsulation (AIDE) technology. The company's lead asset, eDSP, is in Phase III trials for Ataxia-Telangiectasia. As of 2026Q1, 113 institutions hold …